the aid library

Filter

272

Download

View PDF

Challenges and advancements in the development of vaccines and therapies against Chagas disease

Pinazo, M.J.; E. Malchiodi, J.P. Ioset, (2024) CC

The Lancet Volume 5, Issue 10100972October 2024 Chagas Disease Serie 3

Download

View PDF

Standard treatment Guideline for Primary Hospital
recommended

Food, Medicine and Healthcare Administration and Control Authority of Ethiopia (2014) C_WHO

3rd edition!

External Link

Reducing hospital-acquired infections and improving the rational use of antibiotics in a developing country: an effectiveness study

Murni I. K., T. Duke, S. Kinney et al. (2014) C2

Nosocomial infections, or hospital-acquired infec-tions (HAI), are among the most significant causesof morbidity and mortality in healthcare settingsthroughout the world.Prevention of HAIs iscentral to providing high quality and safe health-care, even in settings with limited resources.Transmi ... more

External Link

A Global Research Agenda for Pediatric HIV

M. Penazzato; C. Irvine; M. Vicari; et al Journal of Acquired Immune Deficiency Syndromes (JAIDS); Ovid (2018) CC

Supplement Article www.jaids.com J Acquir Immune Defic Syndr Volume 78, Supplement 1, August 15, 2018

Download

View PDF

Updated recommendations on treatment of adolescents and children with chronic HCV infection
recommended

World Health Organization WHO (2022) C_WHO

The new treatment recommendations that extend the 2018 treat all recommendation for adults with chronic HCV infection to include adolescents and children down to 3 years, and to align the existing recommended pangenotypic direct-acting antiviral (DAA) regimens (SOF/DCV, SOF/VEL and G/P) for adults, ... more

Download

View PDF

ESCMID generic competencies in antimicrobial prescribing and stewardship: towards a European consensus

Dyar O.J., B. Beovic, C. Pulcini et al. Elsevier (2018) C2

Using antimicrobials responsibly is an essential component ofefforts to contain antimicrobial resistance (AMR), and to ensurethat patients receive appropriate treatment. The WHO global action plan on AMR emphasizes the importance of training healthcare professionals in antimicrobial prescribing and ... more

Download

View PDF

Rapid advice : treatment of tuberculosis in children.

World Health Organization (2010) C_WHO

Download

View PDF

Second-Line Antituberculosis Drugs in Children: A Commissioned Review for the World Health Organization 19th Expert Committee on the Selection and Use of Essential Medicines

Malgosia Grzemska, Elizabeth Mathai World Health Organization WHO (2013)

Download

View PDF

Integrated care for older people (‎ICOPE)‎: guidance for person-centred assessment and pathways in primary care
recommended

World Health Organization WHO (2019) C_WHO

The ICOPE guidance for person-centred assessment and pathways in primary care (ICOPE Handbook) helps community health and care workers put the recommendations outlined in the ICOPE Guidelines into practice. The Handbook assists with setting person-centred goals, screening for loss in a range of doma ... more

External Link

World Health Organization (WHO), Regional Office for South-East Asia (2020) C_WHO

Download

View PDF

Pediatric oncology nursing practice in Latin America and the Caribbean

Pan American Health Organisation PAHO (2024) C_WHO

One of the main aims of the WHO Global Initiative for Childhood Cancer and the CureAll Americas framework is to strengthen centers of excellence and promote the training of the health workforce, especially pediatric oncology nurses, specialized in nursing care for children and adolescents with cance ... more

Download

View PDF

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for ... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download

View PDF

Provisional CDC Guidelines for the Use and Safety Monitoring of Bedaquiline Fumarate (Sirturo) for the Treatment of Multidrug-Resistant Tuberculosis

Centers for Disease Control and Prevention (2013) C_CDC

MMWR: Recommendations and Reports / Vol. 62 / No. 9 Morbidity and Mortality Weekly Report October 25, 2013

Standard treatment Guideline for Primary Hospital recommended

Updated recommendations on treatment of adolescents and children with chronic HCV infection recommended

Integrated care for older people (‎ICOPE)‎: guidance for person-centred assessment and pathways in primary care recommended

Standard treatment Guideline for Primary Hospital
recommended

Updated recommendations on treatment of adolescents and children with chronic HCV infection
recommended

Integrated care for older people (‎ICOPE)‎: guidance for person-centred assessment and pathways in primary care
recommended